The determination of real fluid requirements in laparoscopic resection of pheochromocytoma using minimally invasive hemodynamic monitoring: a prospectively designed trial

  • Martin B. NiederleEmail author
  • Edith Fleischmann
  • Barbara Kabon
  • Bruno Niederle
Open Access



Hemodynamic instability is frequently observed during adrenalectomy for pheochromocytoma (PCC). Guidelines recommend liberal preoperative volume administration. However, it is unclear whether fluid deficiency or vasoplegia causes shifting hemodynamics and whether minimally invasive hemodynamic monitoring with esophageal Doppler (EDM) can help visualize intraoperative changes avoiding volume overload and complications.


Ten patients with biochemically verified PCC and five patients with hormonally inactive adrenal tumors (HIAT; control group) were treated following a strict protocol. During laparoscopic adrenalectomy, goal-directed fluid therapy was performed using EDM. Hemodynamic and biochemical data were documented. The primary outcome variables were fluid requirement and hemodynamic parameters.


Applying EDM, total intraoperative fluid administration was slightly higher in PCC patients than in patients with HIAT (2100 ± 516 vs. 1550 ± 622 ml, p = 0.097; 12.9 ± 4.8 vs. 8.3 ± 0.7 ml kg−1 h−1, p = 0.014). Hemodynamics varied considerably within the PCC group and was associated with type and level of secreted catecholamines. Arterial blood pressure and systemic vascular resistance index reached their minimum in the 10-min period after resection of PCC. Without liberal fluid administration, an increase in cardiac index was observed in both groups comparing baseline measurements to end of surgery. This increase was statistically significant only in PCC patients (PCC: 2.31 vs. 3.15 l min−1 m−2, p = 0.005; HIAT: 2.08 vs. 2.56 l min−1 m−2, p = 0.225).


As vasoplegia, but not hypovolemia, was documented after tumor resection, there is no evidence that PCC patients profit from liberal fluid administration during laparoscopic adrenalectomy. To avoid volume overload, noninvasive techniques such as EDM should be routinely used to visualize the variable intraoperative course.

Trial registration:, Identifier: NCT01425710.


Pheochromocytoma Fluid management Advanced intra-operative monitoring Hemodynamics Adrenalectomy Preoperative preparation 

Pheochromocytomas (PCC) are rare adrenal or extraadrenal catecholamine-producing tumors with an estimated incidence of approximately 0.46 to 4.65 per million inhabitants [1, 2]. Surgical resection is the only curative therapy to liberate the patient from its diverse symptoms [3, 4].

The surgical technique of choice is endoscopic adrenalectomy either through transperitoneal or retroperitoneal route [3] and is associated with low surgical morbidity and mortality [5, 6, 7]. However, the perioperative course is often complicated by hemodynamic instability, such as sudden hypertensive or tachycardic episodes during the initiation of pneumoperitoneum/pneumoretroperitoneum and tumor manipulation [8, 9], or severe and prolonged hypotension after tumor removal [7, 10].

Although various retrospective analyses have attempted to identify preoperative risk factors for intra- and postoperative complications, the perioperative course during tumor resection remains unpredictable [5, 7, 11, 12]. Current guidelines still recommend preoperative alpha blockade to avoid hypertensive events during resection and additionally a high-salt diet, liberal fluid intake and infusion therapy (approx. 2 l of saline the evening before surgery) to prevent postoperative hypotensive episodes [3, 13, 14].

Vasoplegia due to sudden fall of catecholamines, but not hypovolemia, has been suspected to be the reason for a substantial decline in arterial blood pressure (ABP) after tumor removal. Therefore, the usefulness of liberal perioperative fluid administration to prevent postresection hypotension has been questioned [8, 15, 16]. Additionally, an ongoing debate surrounds the potential danger and relation to postresection hypotension of preoperative alpha blockade [17, 18, 19, 20, 21]. To our knowledge, intraoperative fluid requirement has not been prospectively investigated as yet, although the potentially negative effects of liberal fluid administration are well recognized [22] and volume overload is present in at least 8% of patients after PCC resection [7].

To early recognize hemodynamic instability intraoperatively and to avoid complications postoperatively, advanced intraoperative hemodynamic monitoring has been recommended in recent guidelines [3, 14]. Initially, pulmonary artery catheter (PAC) [8, 20, 23, 24, 25], an invasive technique with potentially severe complications, was used. However, PAC contrasts the intention of endoscopic surgical procedures to minimize trauma and complications. Therefore, the use of noninvasive methods, such as esophageal Doppler monitoring (EDM) for visualizing cardiac output (CO), systemic vascular resistance (SVR) and fluid responsiveness, seems more rational.

EDM has been shown to be an effective method for advanced hemodynamic monitoring and goal-directed fluid therapy in various types of surgery [26, 27, 28, 29].

Reviewing the literature, only two trials have been published using minimally invasive monitoring techniques during PCC surgery, both during open resection [15, 30]. To our knowledge, noninvasive monitoring systems have so far not been studied in endoscopic PCC removal. Therefore, this is the first study to apply EDM during laparoscopic adrenalectomy for PCC following a precise treatment protocol in an attempt to assess intraoperative fluid requirement and to visualize hemodynamic changes to elucidate the reasons for instability and to provide individualized treatment. Patients with PCC were compared with patients operated for hormonally inactive adrenal tumors (HIAT) receiving exactly the same surgical procedure.

Materials and methods

The trial was conducted at the Departments of Anesthesia and Surgery, Medical University of Vienna. It was approved by the local ethics committee (EK 495/2011) and registered at (Identifier: NCT01425710). All patients signed a written informed consent to all diagnostic and therapeutic procedures. All procedures were carried out in accordance with the Declaration of Helsinki and its later amendments.


A total of 15 patients (PCC: n = 10, HIAT: n = 5 [controls]) were included in this prospective observational study. The patients’ baseline data are presented in Table 1.
Table 1

Baseline characteristics




p value

Patients (f:m)

10 (3:7)

5 (3:2)

Age (years)

56 (± 9)

62 (± 11)


Weight (kg)

78 (± 18)

82 (± 8)


Height (cm)

169 (± 7)

166 (± 10)


BMI (kg/m2)

27 (± 6)

30 (± 5)


ASA score

ASA 2: 9

ASA 1: 1

ASA 3: 1

ASA 2: 4

PCC-specific preoperative symptoms

HA: 4

HTC: 2

TC: 1

None: 3

Diabetes mellitus



Mean phenoxybenzamine end dose/day (mg)

25 (± 15)


Beta blockers



Other AHM



Max. tumor diameter (mm)

55 (± 30)

67 (± 38)


Duration of surgery (min)

139 (± 41)

136 (± 47)


Values are mean (± standard deviation) or number

AHM antihypertensive medication, ASA American Society of Anesthesiologists, BMI body mass index, HIAT hormonally inactive adrenal tumor, PCC pheochromocytoma, TC tachycardia

The histological evaluation revealed benign PCC (eight right-side, two left-side) and various benign adrenocortical lesions in the controls (two right-side, three left-side). Preoperative diagnosis of PCC was confirmed both biochemically (plasma nor-/metanephrines, urinary catecholamines and nor-/metanephrines in 24-h urine collection) and radiologically (fluorodopa positron emission tomography/computed tomography). Conn’s and Cushing’s syndromes were excluded biochemically in the HIAT group.

Preoperative medical preparation

PCC patients received phenoxybenzamine (a nonselective, irreversible alpha blocker) starting 3 weeks before surgery. The initial dose was 5 mg daily for 1 week, then 10 mg in two doses daily for another week and, in the last week, increased by 10 mg every day as needed to achieve the target criteria recommended [31]. The patients were not given alpha blockers on the day of surgery. Already established beta blocker therapy was left unchanged. Other antihypertensive medication was reduced or discontinued to avoid hypotension. The patients did not receive any infusion therapy or special diet. In all subjects, concomitant structural heart disease was initially excluded by transthoracic echocardiography.

Surgical procedure

In all patients, endoscopic adrenalectomy was performed with the transperitoneal flank approach. All tumors were removed en bloc with the surrounding fatty tissue. No selective lymphadenectomy was performed. The specimens were extracted in toto in plastic bags to avoid tumor spillage. Tumor size was measured directly after removal by the surgeon.

Anesthesiological management

All patients were managed by one single anesthetist. Anesthesia was inducted via peripheral venous lines with continuous infusions of remifentanil at 0.5 µg kg−1 min−1 for 1 min followed by injections of 3 mg/kg propofol i.v. as bolus. To avoid any sympathetic activation by painful stimuli, a bispectral index of 40–50 was targeted and anesthesia was continued using sevoflurane (target minimum alveolar concentration 1.1) and continuous infusion of remifentanil at 0.3–0.4 kg−1 min−1. Pressure-controlled ventilation was used targeting a tidal volume of 6–8 ml kg−1 with a positive end-expiratory pressure of 5 mbar before and after pneumoperitoneum and 8 mbar during pneumoperitoneum at a respiratory rate of 10–16 min−1 to maintain normocapnia.

Hemodynamic monitoring and fluid therapy

Before induction of anesthesia, all patients received an arterial line in the radial artery in order to invasively measure ABP. After intubation, a central venous catheter was placed into the right internal jugular vein. The EDM (CardioQ®, Deltex Medical Ltd., UK) was then installed and optimized as recommended by the manufacturer. Stroke volume (SV) and aortic corrected flow time (FTc) were recorded as proposed by the manufacturer and published previously [26]. Goal-directed fluid therapy was performed using balanced crystalloid fluid (Elo-Mel isotone®, Fresenius Kabi, Germany). Beside an initial bolus of 500 ml at the very beginning of surgery, boli of 250 ml was administered to target an FTc of 0.33–0.36 ms and continued if an at least 10% increase in SV was observed. A reassessment was done at least every 10 min or more often in the presence of hemodynamic instability. In the case of hypotension (mean ABP < 60 mmHg) and no response to fluid therapy, norepinephrine was initiated as continuous infusion. In the case of hypertension (systolic ABP > 180 mmHg or mean ABP > 100 mmHg), nitroprusside was administered continuously.

Data collection

FTc, SV, CO and peak velocity (PV) data were collected continuously, and hemodynamic, respiratory and additional parameters were recorded at least every 2 min. The important time-points (incision, creation of pneumoperitoneum, ligature of suprarenal vein, tumor extirpation and end of surgery) were documented. The data were then summarized (mean) for the different intraoperative periods: period 1: intubation until incision; period 2: incision until creation of pneumoperitoneum; period 3: after creation of pneumoperitoneum until ligature of suprarenal vein; period 4: after ligature of suprarenal vein until tumor extirpation; period 5: first 10 min after tumor extirpation; period 6: after tumor extirpation until end of operation. Cardiac index (CI), stroke volume index (SVI), and SVR index (SVRI) were finally calculated using the formula by Mosteller to estimate body surface. Additionally, serum catecholamine levels were measured intraoperatively at seven predefined time-points.

Postoperative outcome

All patients were brought to the post-anesthesia/intensive care units (PACU/ICU) directly after surgery. Hemodynamic parameters and adverse events were documented for 24 h.

Statistical methods

Normal distribution was assessed with the Shapiro–Wilk test and visual histogram inspection. Data are given as mean values (± standard deviation) or median (25th quartile–75th quartile). Following descriptive analysis, the t test was used to compare fluid therapy within the groups and the Wilcoxon signed-rank test was used to compare period 1 to period 6 within each group. p values < 0.05 were considered significant.


Fluid management

Using EDM for goal-directed fluid therapy, the amount of infusion administered intraoperatively was 2100 ml (± 516) in the PCC group as compared to 1550 (± 622) in the HIAT group (p = 0.092). After adjusting for the duration of surgery and body weight, patients with PCC received 12.9 (± 4.8) ml kg−1 h−1 and those with HIAT 8.3 (± 0.7) (p = 0.014). There was a trend toward more fluid given after tumor resection in PCC (about 300 ml additionally) that did not reach the level of significance (see Table 2).
Table 2

Intraoperative fluid therapy and balance




p value

Duration of surgery (min)

139 (± 41)

136 (± 47)


Total fluid given (ml)

2100 (± 516)

1550 (± 622)


 Total fluid given per kg and hour (ml kg−1 h−1)

12.9 (± 4.8)

8.3 (± 0.7)


Blood loss (ml)

52 (± 6)

50 (± 0)


Urine output (ml)

328 (± 182)

218 (± 88)


Fluid balance

1720 (± 370)

1282 (± 580)


Fluid before tumor extirpation (ml)

1640 (± 600)

1450 (± 620)


Fluid after tumor extirpation (ml)

440 (± 360)

100 (± 140)


Values are mean (± standard deviation)

HIAT hormonally inactive adrenal tumor, PCC pheochromocytoma

Hemodynamic and biochemical measurements

The type and maximum level of catecholamines released together with the maximum infusion rate of intraoperative norepinephrine and nitroprusside in PCC patients are presented in Fig. 1. Figure 2 summarizes the means of intraoperative hemodynamic parameters for the six predefined periods as individual curves for each patient.
Fig. 1

Type and maximum level of intraoperative catecholamine release [ng/l] and maximum intraoperative rate of vasoactive medication [µg kg−1 min−1] for each pheochromocytoma (PCC) patient. White bar: norepinephrine, black bar: epinephrine, gray bar: dopamine. Reference values: norepinephrine: < 420 ng/l, epinephrine: < 84 ng/l, dopamine: < 85 ng/l

Fig. 2

Intraoperative hemodynamic parameters. Solid red lines: patients with pheochromocytoma; broken blue lines: patients with hormonally inactive adrenal tumors. 1: Period 1—intubation until incision. 2: Period 2—incision until creation of pneumoperitoneum. 3: Period 3—creation of pneumoperitoneum until ligature of suprarenal vein. 4: Period 4—ligature of suprarenal vein until tumor extirpation. 5: Period 5—first 10 min after tumor extirpation. 6: Period 6—tumor extirpation until end of operation. ABP arterial blood pressure, CI Cardiac Index, FTc aortic corrected flow time, HR heart rate, PV peak velocity, SVI Stroke Volume Index, SVRI Systemic Vascular Resistance Index (Color figure online)

The mean arterial blood pressure was held constant throughout surgery following the study protocol. Median FTc was within the targeted range at the end of surgery and increased in both groups.

All other hemodynamic measurements were very heterogeneous within the PCC group, whereas the patients with HIAT showed no marked differences (Fig. 2).

Especially in periods 3 (creation of pneumoperitoneum until ligature of suprarenal vein) and 4 (ligature of suprarenal vein until tumor extirpation), eight of ten (80%) patients with PCC showed a strong increase in CI during tumor manipulation. The four patients with the highest intraoperative peak CI (more than 4 l min−1 m−2) were among those with the highest intraoperative epinephrine blood levels (> 7000 ng/l; patients 3, 8, 5, 1). In accordance with CI, the PV peaked during tumor manipulation and then slowly decreased toward the end of surgery in all PCC patients but one (90%). Again, the three patients with maximum PV (above 120 cm/s) were among those with the highest epinephrine peak levels (patients 3, 5 and 8).

Intraoperative heart rate (HR) was constant in the HIAT patients and shifted markedly along the operations within the other group. Once more, there was a rise in HR in all patients with PCC (100%) during tumor manipulation (periods 3 and 4). The patients with the highest HR were again among those with markedly elevated epinephrine levels (patients 8, 2, 1, 3).

Table 3 presents the changes between baseline and end of operation. Both PV and HR increased significantly in the PCC patients (p = 0.007 and p = 0.005, respectively), while within the HIAT group, there was no difference in PV (p = 0.225) and a smaller but significant increase in HR (p = 0.043) comparing baseline measurements to end of surgery.
Table 3

Comparison between period 1 (before incision) and period 6 (end of surgery)






p value



p value

CI (l min−1 m−2)

2.31 (1.85–2.41)

3.15 (2.46–4.24)


2.08 (1.64–2.11)

2.56 (2.35–2.83)


SVRI (dyn s cm−5 m−2)

1815 (1473–2346)

1802 (1297–1982)a


2469 (2468–2528)

1813 (1528–2179)


PV (cm s−1)

69.1 (62.2–72.5)

93.4 (75.4–103.0)


53.0 (50.8–58.1)

77.4 (64.0–78.4)


SVI (ml/m−2)

37.5 (33.7–41.1)

37.0 (33.3–52.2)


38.2 (33.7–44.1)

49.7 (44.1–50.9)


FTc (ms)

304 (298–319)

344 (310–350)


311 (305–327)

332 (306–343)


MAP (mmHg)

68 (62–75)

80 (66–96)


71 (66–75)

84 (84–105)


HR (min−1)

60 (54–65)

104 (95–111)


48 (48–51)

71 (61–76)


Values are median (interquartile range)

a4 patients still on norepinephrine > 0.05 µg kg−1 min−1

CI Cardiac Index, FTc aortic corrected flow time, HIAT hormonally inactive adrenal tumor, HR heart rate, MAP mean arterial pressure, PCC pheochromocytoma, PV peak velocity, SVI Stroke Volume Index, SVRI Systemic Vascular Resistance Index

Table 4 focuses on the hemodynamic situation 10 min after tumor removal (period 5). In 8/10 (80%) patients with PCC, the lowest SVRI levels were reached within or immediately before this period (1/10 patients, 10%). Additionally, in this phase of surgery, the median SVRI of the patients in the PCC group was markedly decreased to 1337 (1244–1632) dyn s cm−5 m−2, although all PCC patients received their maximum norepinephrine dose within this period (see Fig. 1). Two patients showed a strongly decreased SVRI of lower than 1000 dyn s cm−5 m−2 (patients 3 and 8). Mean ABP was lowest in period 5 in all PCC patients but one (90%).
Table 4

Hemodynamic parameters (median, interquartile range) during period 5 (first 10 min after tumor removal)




CI (l min−1 m−2)

3.24 (2.83–3.54)

2.56 (2.54–2.77)

SVRI (dyn s cm−5 m−2)

1337 (1244–1632)

1528 (1482–1855)

PV (cm s−1)

90.8 (75.4–95.5)

78.4 (77.4–78.6)

SVI (ml/m−2)

34.7 (31.4–44.6)

50.0 (45.1–49.7)

FTc (ms)

317 (282–344)

333 (310–343)

MAP (mmHg)

66 (55–70)

62 (62–67)

HR (min−1)

87 (76–97)

56 (56–56)

Norepinephrine infusion rate (µg kg−1 min−1)

0.08 (0.04–0.33)

0.06 (0.05–0.07)

Values are median (interquartile range)

CI Cardiac Index, FTc aortic corrected flow time, HIAT hormonally inactive adrenal tumor, HR heart rate, MAP mean arterial pressure, PCC pheochromocytoma, PV peak velocity, SVI Stroke Volume Index, SVRI Systemic Vascular Resistance Index

Postoperative outcomes

The postoperative course was uneventful in 12 patients. All but two patients with PCC left the operation room without catecholamine support. Of these two patients, one (patient 8) showed massively reduced SVRI (906 dyn s cm−5 m−2) but a sufficient CI of 4.6 l min−1 m−2 and FTc within the target range at 346 ms by the end of the surgical procedure. This patient required the highest intra-operative norepinephrine infusion. As the subject’s blood pressure could not be elevated to a mean arterial pressure (MAP) over 60 mmHg with norepinephrine alone, a vasopressin infusion was added (out of protocol). Both infusions were discontinued within 24 h after surgery. The second patient (patient 7) had a low SVRI of 1561 dyn s cm−5 m−2 but could be weaned from catecholamine within 6 h. Both patients received beta blockers prior to surgery (see Table 1) and had a HR of lower than the 25th percentile of the PCC group at the PACU/ICU.

Though experiencing normal MAP by the end of surgery, one other PCC patient required catecholamine support 2 h later. A hematoma was documented in the abdominal wall (max. diameter 9 cm) and blood pressure normalized after infusion of two units of red packed blood cells.


The perioperative management of PCC during endoscopic adrenalectomy requires close interdisciplinary cooperation between endocrine surgeons and anesthesiologists and has been under intensive debate [5, 14, 32].

Whilst guidelines recommend liberal fluid administration pre- and perioperatively to correct hypovolemia and to avoid hypotension after tumor resection [3, 14], some experts have challenged these recommendations [18, 33, 34]. Since intraoperative hemodynamics are extremely unpredictable, extended monitoring seems mandatory especially in large tumors to provide individualized therapy and to avoid overly liberal and potentially harmful fluid administration [15, 16, 18, 33], as found in at least 8% of PCC patients perioperatively [7].

To our knowledge, this is the first prospectively designed controlled trial to address hemodynamic changes and fluid demand during laparoscopic adrenalectomy in patients with PCC performing intraoperative noninvasive monitoring by using the esophageal Doppler technique.

The total amount of volume needed to optimize CO parameters was not excessively high in the PCC patients, even though these patients did not receive additional preoperative fluid therapy. The differences of 550 ml or 4 ml kg−1 h−1 between PCC and HIAT do not indicate that fluid deficiency was responsible for intra- or postoperative hemodynamic instability, since a substantial amount of the additional fluid was administered as “fluid trials” in response to low ABP after tumor resection. EDM visualized a reduction in SVRI directly after tumor removal in all patients with PCC. Additionally, prolonged hypotension was always associated with very low SVRI without signs of hypovolemia. These findings contrast guidelines suggesting fluid deficiency to be causative for hemodynamic instability [3, 14]. Our observations are in accordance with comparable previous studies using either pulmonary artery catheter [8] or performed during open surgery [15]. Vasoplegia was previously assumed to be responsible for hypotension [18]. However, prospectively collected data addressing the fluid status of PCC patients are still missing.

The marked increase in HR shown here was not observed in the only comparable study published by Joris et al. [8]. However, all patients in their investigation received beta blockers either intraoperatively or preoperatively. It is well known that hypotension due to SVR reduction (e.g., due to spinal anesthesia) results in both compensatory tachycardia and an increase in CO and is thereby best treated by applying alpha adrenoreceptor agonists but not excessive volume administration [35, 36]. Compatible to this, the two patients who required catecholamine infusions by the end of surgery in this study had normal or high CI but markedly reduced SVRI and failed to respond to fluid trials. Interestingly, both subjects were on beta blockers preoperatively and had low HR compared to the other PCC patients. Another patient (PCC #3) had comparably low SVRI (< 1000 dyn s cm−5 m−2) posttumor resection. This patient did not receive beta blocker therapy and had the highest CI, a HR of 110 bpm and normal ABP by the end of surgery. Thus, it seems possible that in the two patients with prolonged hypotension, the beta blockers inhibited compensatory tachycardia which is needed for normalization of ABP. Long-acting beta blockers should therefore be used with caution prior to surgery.

It cannot be excluded that reduction in SVRI in PCC patients is at least partially influenced by preoperative alpha adrenoreceptor blockade, as shown by Groeben et al. [19]. Although no patient in the present study received an alpha blocker on the day of surgery, individual pharmacodynamics could be responsible for the duration and amount of the postoperative effect, as the duration of phenoxybenzamine action may vary and depends on the velocity of alpha receptor resynthetization [37]. Advanced low-invasive hemodynamic monitoring may also assist in identifying these patients during operation with prolonged reduction in SVR who might profit most from advanced postoperative care [38].

Our data suggest that there is no rationale for preoperative fluid therapy as recommended in guidelines or even excessive fluid administration (up to 6 l of saline 0.9% within 48 h preoperatively have been reported even recently [39]). Normalizing hypertension with antihypertensive drugs (in our trial, treatment was started at least 3 weeks before surgery) should help “normalize” fluid status, if at all altered. Therefore, there is no rationale for any additional infusion therapy before surgery, as it is well understood that unnecessary administration of crystalloid fluids (especially saline) may have detrimental effects as well [22, 40]. The results of this trial thereby again underline that targeted and individualized volume management—increasingly claimed [41] in general—is essential but even more important for patients with cardiovascular abnormalities (such as catecholamine excess).

The fact is to be kept in mind that intraoperative courses may prove totally uneventful or definitively turbulent in PCC patients.

Closely monitoring the extremely diverse hemodynamic course during PCC surgery using minimally invasive techniques may help optimize and standardize anesthesiology management [42] and could avoid unnecessary or even harmful liberal use of fluids.

Although this trial was designed as an exploratory study and the small sample size may thus be a limitation, its strengths are its prospective and standardized study design and that the controls received the same surgery with an identical anesthetic protocol performed by the same anesthetist, thereby minimizing confounders. Therefore, providing a higher level of evidence than previous retrospective trials, our results may induce a critical reflexion of current perioperative concepts in perioperative management for laparoscopic adrenalectomy in PCC. Based on our preliminary data, a prospective randomized trial could compare different fluid management strategies regarding hemodynamic stability and outcomes in a larger number of PCC patients.

In conclusion, there is no evidence that PCC patients profit from liberal perioperative fluid administration. Reduction of SVRI, but not hypovolemia, is most likely the reason for hypotension after removal of a PCC. As hemodynamics and catecholamine levels vary extremely among PCC and are hardly predictable, EDM is a helpful and less invasive tool for advanced intraoperative monitoring and should be routinely used to provide individualized management during laparoscopic adrenalectomy for PCC.



Open access funding provided by Medical University of Vienna. The authors wish to thank Mr. Oliver Zotti for his essential help throughout the study. Additionally, the authors are grateful to the Medical Simulation and Emergency Management Research Group, Department of Anesthesia, Medical University of Vienna (Prof. Karl Schebesta, Prof. Bernhard Rössler) for their important logistic support.

Compliance with ethical standards


Drs. Martin B. Niederle, Edith Fleischmann, Barbara Kabon and Bruno Niederle have no conflicts of interest or financial ties to disclose.


  1. 1.
    Berends AMA, Buitenwerf E, de Krijger RR, Veeger N, van der Horst-Schrivers ANA, Links TP, Kerstens MN (2018) Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med 51:68–73CrossRefGoogle Scholar
  2. 2.
    Ebbehoj A, Sondergaard E, Trolle C, Stochholm K, Poulsen P (2017) The epidemiology of pheochromocytoma: increasing incidence and changing clinical presentation. A population-based retrospective study 1977–2015. Endocrine Abstracts 49.
  3. 3.
    Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr, Endocrine S (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915–1942CrossRefGoogle Scholar
  4. 4.
    Beninato T, Kluijfhout WP, Drake FT, Lim J, Kwon JS, Xiong M, Shen WT, Gosnell JE, Liu C, Suh I, Duh QY (2017) Resection of pheochromocytoma improves diabetes mellitus in the majority of patients. Ann Surg Oncol 24:1208–1213CrossRefGoogle Scholar
  5. 5.
    Gaujoux S, Bonnet S, Lentschener C, Thillois JM, Duboc D, Bertherat J, Samama CM, Dousset B (2016) Preoperative risk factors of hemodynamic instability during laparoscopic adrenalectomy for pheochromocytoma. Surg Endosc 30:2984–2993CrossRefGoogle Scholar
  6. 6.
    Livingstone M, Duttchen K, Thompson J, Sunderani Z, Hawboldt G, Sarah Rose M, Pasieka J (2015) Hemodynamic stability during pheochromocytoma resection: lessons learned over the last two decades. Ann Surg Oncol 22:4175–4180CrossRefGoogle Scholar
  7. 7.
    Weingarten TN, Welch TL, Moore TL, Walters GF, Whipple JL, Cavalcante A, Bancos I, Young WF Jr, Gruber LM, Shah MZ, McKenzie TJ, Schroeder DR, Sprung J (2017) Preoperative levels of catecholamines and metanephrines and intraoperative hemodynamics of patients undergoing pheochromocytoma and paraganglioma resection. Urology 100:131–138CrossRefGoogle Scholar
  8. 8.
    Joris JL, Hamoir EE, Hartstein GM, Meurisse MR, Hubert BM, Charlier CJ, Lamy ML (1999) Hemodynamic changes and catecholamine release during laparoscopic adrenalectomy for pheochromocytoma. Anesth Analg 88:16–21Google Scholar
  9. 9.
    Wu G, Zhang B, Yu C, Gao L, Gao Y, Huang Y, Yu L, Zhang G, Yang L, Yuan J (2013) Effect of early adrenal vein ligation on blood pressure and catecholeamine fluctuation during laparoscopic adrenalectomy for pheochromocytoma. Urology 82:606–611CrossRefGoogle Scholar
  10. 10.
    Namekawa T, Utsumi T, Kawamura K, Kamiya N, Imamoto T, Takiguchi T, Hashimoto N, Tanaka T, Naya Y, Suzuki H, Ichikawa T (2016) Clinical predictors of prolonged postresection hypotension after laparoscopic adrenalectomy for pheochromocytoma. Surgery 159:763–770CrossRefGoogle Scholar
  11. 11.
    Bruynzeel H, Feelders RA, Groenland TH, van den Meiracker AH, van Eijck CH, Lange JF, de Herder WW, Kazemier G (2010) Risk factors for hemodynamic instability during surgery for pheochromocytoma. J Clin Endocrinol Metab 95:678–685CrossRefGoogle Scholar
  12. 12.
    Kiernan CM, Du L, Chen X, Broome JT, Shi C, Peters MF, Solorzano CC (2014) Predictors of hemodynamic instability during surgery for pheochromocytoma. Ann Surg Oncol 21:3865–3871CrossRefGoogle Scholar
  13. 13.
    Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K, North American Neuroendocrine Tumor S (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39:775–783CrossRefGoogle Scholar
  14. 14.
    Stefanidis D, Goldfarb M, Kercher KW, Hope WW, Richardson W, Fanelli RD, Society of G, Endoscopic S (2013) SAGES guidelines for minimally invasive treatment of adrenal pathology. Surg Endosc 27:3960–3980CrossRefGoogle Scholar
  15. 15.
    Mallat J, Pironkov A, Destandau MS, Tavernier B (2003) Systolic pressure variation (Deltadown) can guide fluid therapy during pheochromocytoma surgery. Can J Anaesth 50:998–1003CrossRefGoogle Scholar
  16. 16.
    Iijima T, Takagi T, Iwao Y (2004) An increased circulating blood volume does not prevent hypotension after pheochromocytoma resection. Can J Anaesth 51:212–215CrossRefGoogle Scholar
  17. 17.
    Lentschener C, Gaujoux S, Baillard C, Dousset B (2016) Inappropriate adrenoreceptor blockade prior to phaeochromocytoma removal is perhaps a ‘timely reappraisal’? Clin Endocrinol 85:989–990CrossRefGoogle Scholar
  18. 18.
    Lentschener C, Gaujoux S, Tesniere A, Dousset B (2011) Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal? Eur J Endocrinol 165:365–373CrossRefGoogle Scholar
  19. 19.
    Groeben H, Nottebaum BJ, Alesina PF, Traut A, Neumann HP, Walz MK (2017) Perioperative alpha-receptor blockade in phaeochromocytoma surgery: an observational case series. Br J Anaesth 118:182–189CrossRefGoogle Scholar
  20. 20.
    Kinney MA, Narr BJ, Warner MA (2002) Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 16:359–369CrossRefGoogle Scholar
  21. 21.
    Randle RW, Balentine CJ, Pitt SC, Schneider DF, Sippel RS (2017) Selective versus non-selective alpha-blockade prior to laparoscopic adrenalectomy for pheochromocytoma. Ann Surg Oncol 24:244–250CrossRefGoogle Scholar
  22. 22.
    Gupta R, Gan TJ (2016) Peri-operative fluid management to enhance recovery. Anaesthesia 71:40–45CrossRefGoogle Scholar
  23. 23.
    Kinney MA, Warner ME, vanHeerden JA, Horlocker TT, Young WF Jr, Schroeder DR, Maxson PM, Warner MA (2000) Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg 91:1118–1123Google Scholar
  24. 24.
    Mihm FG (1983) Pulmonary artery pressure monitoring in patients with pheochromocytoma. Anesth Analg 62:1129–1133CrossRefGoogle Scholar
  25. 25.
    Colson P, Ryckwaert F, Ribstein J, Mann C, Dareau S (1998) Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery. Acta Anaesthesiol Scand 42:1114–1119CrossRefGoogle Scholar
  26. 26.
    Gan TJ, Soppitt A, Maroof M, El-Moalem H, Robertson KM, Moretti E, Dwane P, Glass PS (2002) Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology 97:820–826CrossRefGoogle Scholar
  27. 27.
    Venn R, Steele A, Richardson P, Poloniecki J, Grounds M, Newman P (2002) Randomized controlled trial to investigate influence of the fluid challenge on duration of hospital stay and perioperative morbidity in patients with hip fractures. Br J Anaesth 88:65–71CrossRefGoogle Scholar
  28. 28.
    Wakeling HG, McFall MR, Jenkins CS, Woods WG, Miles WF, Barclay GR, Fleming SC (2005) Intraoperative oesophageal Doppler guided fluid management shortens postoperative hospital stay after major bowel surgery. Br J Anaesth 95:634–642CrossRefGoogle Scholar
  29. 29.
    Okrainec A, Bergman S, Demyttenaere S, Feldman LS, Nutting A, Carli F, Fried GM (2007) Validation of esophageal Doppler for noninvasive hemodynamic monitoring under pneumoperitoneum. Surg Endosc 21:1349–1353CrossRefGoogle Scholar
  30. 30.
    Matsuda Y, Kawate H, Shimada S, Matsuzaki C, Nagata H, Adachi M, Ohnaka K, Nomura M, Takayanagi R (2014) Perioperative sequential monitoring of hemodynamic parameters in patients with pheochromocytoma using the non-invasive cardiac system (NICaS). Endocr J 61:571–575CrossRefGoogle Scholar
  31. 31.
    Roizen MF, Hunt TK, Beaupre PN, Kremer P, Firmin R, Chang CN, Alpert RA, Thomas CJ, Tyrrell JB, Cahalan MK (1983) The effect of alpha-adrenergic blockade on cardiac performance and tissue oxygen delivery during excision of pheochromocytoma. Surgery 94:941–945Google Scholar
  32. 32.
    Brunaud L, Nguyen-Thi PL, Mirallie E, Raffaelli M, Vriens M, Theveniaud PE, Boutami M, Finnerty BM, Vorselaars WM, Rinkes IB, Bellantone R, Lombardi C, Fahey T 3rd, Zarnegar R, Bresler L (2016) Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: a multicenter retrospective analysis in 225 patients. Surg Endosc 30:1051–1059CrossRefGoogle Scholar
  33. 33.
    Connor D, Boumphrey S (2016) Perioperative care of phaeochromocytoma. BJA Educ 16:153–158CrossRefGoogle Scholar
  34. 34.
    James MFM (2010) Anaesthesia for patients with endocrine disease. Oxford University Press, OxfordGoogle Scholar
  35. 35.
    Dyer RA, Reed AR, van Dyk D, Arcache MJ, Hodges O, Lombard CJ, Greenwood J, James MF (2009) Hemodynamic effects of ephedrine, phenylephrine, and the coadministration of phenylephrine with oxytocin during spinal anesthesia for elective cesarean delivery. Anesthesiology 111:753–765CrossRefGoogle Scholar
  36. 36.
    Langesaeter E, Rosseland LA, Stubhaug A (2008) Continuous invasive blood pressure and cardiac output monitoring during cesarean delivery: a randomized, double-blind comparison of low-dose versus high-dose spinal anesthesia with intravenous phenylephrine or placebo infusion. Anesthesiology 109:856–863CrossRefGoogle Scholar
  37. 37.
    Peck T (2008) Pharmacology for anaesthesia and intensive care, 3rd edn. Cambridge University Press, New YorkCrossRefGoogle Scholar
  38. 38.
    Lentschener C, Gaujoux S, Mion G, Dousset B, Baillard C (2018) Most patients undergoing phaeochromocytoma removal could be safely discharged from the post-anaesthesia care unit to the ward after three hours monitoring. Br J Anaesth 120:879–880CrossRefGoogle Scholar
  39. 39.
    Challis BG, Casey RT, Simpson HL, Gurnell M (2017) Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma? Clin Endocrinol 86:163–167CrossRefGoogle Scholar
  40. 40.
    Bellamy MC (2006) Wet, dry or something else? Br J Anaesth 97:755–757CrossRefGoogle Scholar
  41. 41.
    Wilson RTJ, Minto G (2017) The great fluid debate: time for Flexit? Br J Anaesth 118:819–822CrossRefGoogle Scholar
  42. 42.
    Vorselaars W, Postma EL, Mirallie E, Thiery J, Lustgarten M, Pasternak JD, Bellantone R, Raffaelli M, Fahey T 3rd, Vriens MR, Bresler L, Brunaud L, Zarnegar R (2018) Hemodynamic instability during surgery for pheochromocytoma: comparing the transperitoneal and retroperitoneal approach in a multicenter analysis of 341 patients. Surgery 163:176–182CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of Anesthesia, General Intensive Care and Pain ManagementMedical University of ViennaViennaAustria
  2. 2.Division of General Surgery, Section Endocrine Surgery, Department of SurgeryMedical University of ViennaViennaAustria

Personalised recommendations